Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Experts in oncology discuss future directions in biomarker-driven therapy.

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Dr Jyoti Patel presents data from the ARROW clinical trial.

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

Expert oncologists discuss RET-driven therapy for select solid tumors.

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors. 

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.